Double maintains 2 strategies that include RVMD - Revolution Medicines, Inc.
Current Value
$37.861 Year Return
Current Value
$37.861 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 65.02% | $4.95B | 0.35% |
GNOM | 60.31% | $44.43M | 0.5% |
IBB | 57.10% | $5.36B | 0.45% |
PTH | 53.69% | $101.07M | 0.6% |
XPH | 53.19% | $149.79M | 0.35% |
IWO | 53.07% | $11.48B | 0.24% |
ARKG | 52.88% | $1.05B | 0.75% |
PBE | 52.78% | $223.24M | 0.58% |
ISCG | 51.50% | $679.06M | 0.06% |
KJUL | 50.95% | $120.75M | 0.79% |
IWC | 50.83% | $824.65M | 0.6% |
VTWO | 50.75% | $13.29B | 0.07% |
KJAN | 50.71% | $289.38M | 0.79% |
TMSL | 50.65% | $847.12M | 0.55% |
IWM | 50.58% | $64.00B | 0.19% |
SCHA | 50.46% | $17.26B | 0.04% |
VBK | 50.19% | $18.97B | 0.07% |
RDTE | 49.71% | $138.47M | 0.97% |
ESML | 49.59% | $1.84B | 0.17% |
VXF | 49.55% | $22.24B | 0.05% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -15.91% | $23.98B | +34.66% | 1.10% |
PSQH | -9.92% | $93.81M | -45.36% | 0.00% |
LITB | -9.85% | $21.70M | -78.27% | 0.00% |
CME | -6.16% | $99.01B | +39.76% | 3.87% |
K | -6.12% | $27.41B | +36.96% | 2.88% |
ED | -5.30% | $35.36B | +9.76% | 3.39% |
COR | -5.22% | $58.03B | +32.90% | 0.72% |
MKTX | -4.92% | $8.23B | +9.48% | 1.37% |
LTM | -4.39% | $12.12B | -95.54% | 2.48% |
CODI | -4.22% | $461.95M | -71.95% | 16.10% |
VHC | -3.64% | $45.90M | +59.26% | 0.00% |
AWK | -3.52% | $26.90B | +6.78% | 2.27% |
BGS | -3.49% | $350.31M | -45.67% | 18.11% |
AQB | -3.28% | $2.84M | -54.35% | 0.00% |
HUSA | -2.61% | $22.94M | -6.82% | 0.00% |
ZCMD | -2.47% | $28.79M | -13.64% | 0.00% |
VSA | -2.35% | $8.67M | -15.70% | 0.00% |
AIFU | -2.28% | $6.13B | +82.50% | 0.00% |
AMT | -2.00% | $101.95B | +12.04% | 3.05% |
OXBR | -1.39% | $13.03M | -26.47% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRNX | 55.49% | $2.81B | -33.11% | 0.00% |
RARE | 52.56% | $3.45B | -11.14% | 0.00% |
KYMR | 52.33% | $2.87B | +47.81% | 0.00% |
DYN | 51.36% | $1.09B | -72.88% | 0.00% |
OCUL | 51.21% | $1.47B | +34.80% | 0.00% |
IDYA | 51.01% | $1.87B | -39.13% | 0.00% |
IMVT | 50.84% | $2.75B | -39.02% | 0.00% |
NRIX | 50.67% | $887.38M | -44.23% | 0.00% |
CLDX | 50.41% | $1.35B | -45.18% | 0.00% |
RNA | 50.23% | $3.50B | -28.94% | 0.00% |
CGON | 50.20% | $1.98B | -17.80% | 0.00% |
DNLI | 49.52% | $2.05B | -39.28% | 0.00% |
XENE | 48.87% | $2.49B | -16.90% | 0.00% |
DAWN | 48.84% | $655.81M | -53.05% | 0.00% |
BHVN | 47.96% | $1.44B | -59.41% | 0.00% |
NUVL | 47.64% | $5.72B | +5.04% | 0.00% |
ZYME | 47.58% | $876.06M | +46.53% | 0.00% |
BEAM | 47.43% | $1.69B | -28.30% | 0.00% |
IMNM | 47.41% | $763.10M | -27.52% | 0.00% |
KRYS | 46.98% | $4.01B | -24.37% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -42.92% | $99.76M | 0.59% |
VIXY | -36.99% | $165.69M | 0.85% |
BTAL | -31.41% | $296.79M | 1.43% |
IVOL | -21.55% | $349.27M | 1.02% |
FTSD | -20.81% | $231.79M | 0.25% |
SHYM | -20.60% | $350.04M | 0.35% |
ULST | -19.56% | $662.59M | 0.2% |
XONE | -18.15% | $585.86M | 0.03% |
BSMW | -17.48% | $107.26M | 0.18% |
SPTS | -17.36% | $5.78B | 0.03% |
SCHO | -15.73% | $11.46B | 0.03% |
FXY | -14.71% | $815.67M | 0.4% |
IBTH | -14.64% | $1.60B | 0.07% |
VGSH | -14.61% | $22.80B | 0.03% |
UTWO | -14.50% | $379.36M | 0.15% |
IBTI | -14.40% | $1.06B | 0.07% |
TPMN | -13.42% | $30.81M | 0.65% |
IEI | -13.36% | $15.37B | 0.15% |
AGZ | -12.93% | $614.02M | 0.2% |
VGIT | -12.91% | $31.83B | 0.04% |
Finnhub
Revolution Medicines, Inc. added to Russell Midcap Value Index...
Finnhub
Revolution Medicines, Inc. dropped from Russell 3000 Growth Index...
Finnhub
Revolution Medicines, Inc. dropped from Russell 2000 Dynamic Index...
Yahoo
REDWOOD CITY, Calif. & MIAMI, June 30, 2025--Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinical
Finnhub
Revolution Medicines, Inc. dropped from Russell Small Cap Comp Growth Index...
Finnhub
Revolution Medicines, Inc. added to Russell 1000 Dynamic Index...
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
UNG | 0.02% | $359.91M | 1.06% |
GNMA | -0.12% | $368.58M | 0.1% |
MTBA | -0.20% | $1.38B | 0.17% |
TLTW | 0.26% | $1.14B | 0.35% |
SPAB | -0.28% | $8.80B | 0.03% |
BKAG | -0.31% | $1.90B | 0% |
FXE | 0.36% | $568.58M | 0.4% |
EDV | -0.40% | $3.48B | 0.05% |
XBIL | -0.41% | $783.57M | 0.15% |
MUB | 0.41% | $38.46B | 0.05% |
LGOV | -0.45% | $708.16M | 0.67% |
AGG | -0.45% | $129.00B | 0.03% |
ZROZ | -0.49% | $1.51B | 0.15% |
IBMO | -0.54% | $526.04M | 0.18% |
EUSB | 0.55% | $734.55M | 0.12% |
FBND | 0.57% | $19.25B | 0.36% |
EAGG | -0.59% | $3.99B | 0.1% |
GOVZ | -0.60% | $270.29M | 0.1% |
UCON | 0.68% | $2.98B | 0.86% |
SPSK | -0.73% | $316.15M | 0.5% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VSTA | -0.06% | $342.46M | +40.00% | 0.00% |
DFDV | -0.09% | $247.94M | +1,821.34% | 0.00% |
MOH | -0.29% | $16.10B | -0.08% | 0.00% |
TEF | 0.35% | $29.29B | +23.28% | 6.30% |
EXC | -0.35% | $43.32B | +23.98% | 3.65% |
DOGZ | -0.37% | $363.33M | +65.16% | 0.00% |
CNC | 0.42% | $26.87B | -18.57% | 0.00% |
ACHC | 0.54% | $2.02B | -67.57% | 0.00% |
DG | 0.58% | $25.19B | -13.45% | 2.07% |
PRPO | 0.72% | $16.43M | +109.40% | 0.00% |
CYCN | 0.89% | $9.63M | +30.43% | 0.00% |
CIG.C | -1.00% | $2.64B | +19.84% | 0.00% |
BPT | 1.07% | $11.00M | -79.19% | 0.00% |
CCRN | 1.12% | $419.30M | -7.59% | 0.00% |
KO | -1.15% | $302.72B | +10.49% | 2.83% |
CL | 1.21% | $71.89B | -8.58% | 2.28% |
NEUE | 1.26% | $61.96M | +27.57% | 0.00% |
MCK | 1.30% | $90.65B | +24.27% | 0.39% |
VZ | 1.35% | $178.39B | +2.59% | 6.38% |
OXBR | -1.39% | $13.03M | -26.47% | 0.00% |